Australian Dry Eye

Click here to edit subtitle


view:  full / summary

Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

Posted on January 24, 2021 at 6:55 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced positive top-line symptom, redness, and Schirmer’s test results from the run-in cohort of the Phase 3 TRANQUILITY clinical trial in patients with dry eye disease.

The double-masked, single-center, parallel-group run-in cohort enrolled 23 patients: 12 patients were randomized to receive 0.25% reproxalap ophthalmic solution and 11 patients were randomized to receive veh...

Read Full Post »

IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Pain

Posted on January 10, 2021 at 7:55 AM


  • Ocular Pain, a $10+ billion global market, with significant unmet medical need
  • License agreement aims to accelerate global development of DENKIs, leveraging expertise and resources of both companies


Irvine, Calif., Paris, Hong Kong, Jan. 7, 2021 /PRNewswire/ — IACTA Pharmaceuticals, Inc. (“IACTA" and Pharmaleads, with Pharmaleads Greater China, today announced they have entered into licensing agreements, with ...

Read Full Post »

SilkTech completes enrollment in trial of biological dry eye treatment candidate

Posted on November 28, 2020 at 7:00 AM

SilkTech Biopharmaceuticals has completed enrollment in a phase 2b clinical trial of SDP-4, its eye drop formulation for the treatment of the signs and symptoms of dry eye disease, according to a press release.


The randomized, double-masked, vehicle-controlled, multicenter trial is evaluating the safety and efficacy of SDP-4 at 0.1%, 1% and 3% concentrations in 305 patients at 25 U.S. sites.


SDP-4, a biotherapeutic naturally derive...

Read Full Post »

Phase 2b trial for Aerie dry eye drop begins

Posted on November 16, 2020 at 8:20 AM


A phase 2b clinical trial of AR-15512 ophthalmic solution for the treatment of dry eye disease has been initiated, according to a press release from Aerie Pharmaceuticals.


COMET-1 is a randomized, double-masked, vehicle-controlled trial investigating the safety and efficacy of AR-15512, a TRPM8 agonist. The trial aims to enroll about 360 patients who will receive AR-15512 0.0014%, AR-15512 0.003% or AR-15512 vehicle, one drop twice daily in e...

Read Full Post »

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

Posted on November 7, 2020 at 5:55 PM

Azura Ophthalmics Ltd., a clinical-stage company developing innovative therapies for Meibomian gland dysfunction (MGD) and related eye diseases, today announced a US$20 million financing. The round was led by a syndicate of existing investors including OrbiMed, TPG Biotech, Brandon Capital’s Medical Research Commercialization Fund (MRCF) and Ganot Capital.


On the back of encouraging Phase 2 data to date proceeds from the funding round will be used to advance AzuraR...

Read Full Post »